307 related articles for article (PubMed ID: 10756599)
21. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
22. Assessment of inhibin and p53 in granulosa cell tumors of the ovary.
Gebhart JB; Roche PC; Keeney GL; Lesnick TG; Podratz KC
Gynecol Oncol; 2000 May; 77(2):232-6. PubMed ID: 10785470
[TBL] [Abstract][Full Text] [Related]
23. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
24. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
25. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry.
Henriksen R; Strang P; Wilander E; Bäckström T; Tribukait B; Oberg K
Gynecol Oncol; 1994 Jun; 53(3):301-6. PubMed ID: 8206402
[TBL] [Abstract][Full Text] [Related]
26. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
Vogl FD; Frey M; Kreienberg R; Runnebaum IB
Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359
[TBL] [Abstract][Full Text] [Related]
27. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of p53 accumulation in epithelial ovarian carcinomas.
Berker B; Dunder I; Ensari A; Cengiz SD
Arch Gynecol Obstet; 2002 Aug; 266(4):205-9. PubMed ID: 12192480
[TBL] [Abstract][Full Text] [Related]
30. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
31. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
32. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
Kuwata T; Kitagawa M; Takemura T; Hirokawa K
Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
[TBL] [Abstract][Full Text] [Related]
33. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
34. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
35. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
36. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
38. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
39. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
40. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
